论文部分内容阅读
60例口服降糖药物治疗血糖控制不佳的T2DM患者(HbA1c>8.5%)随机分为2组,停用所有口服降糖药物,其中一组给予诺和锐特充联合来得时MD1降糖治疗,另一组给予诺和锐特充CSII治疗。以空腹血糖<6.0mmol/L并餐后2小时血糖<8.0mmol/L为治疗目标,用动态血糖仪检测患者血糖水平,计算SDBG、MAGE以及空腹血糖变异系数(CV-FPG)作为反映血糖波动的指数。结果CSII组的SDBG(1.01±0.32 vs 1.38±0.21)、MAGE(2.32±0.97 vs 3.54±1.05)、CV-FPG(9.86±4.45 vs 15.62±5.23)均低于MDI组(P<0.05),低血糖发生人次数也低于MDI组,但无统计学意义(P>0.05)。结论比MD1更加有利于血糖的平稳。
Sixty patients with T2DM with poor glycemic control (HbA1c> 8.5%) were randomized into two groups and all the oral hypoglycemic agents were discontinued. One of the two groups was given Novolin combined with MD1 hypoglycemic therapy , And the other group to promise and sharp charge CSII treatment. To fasting blood glucose <6.0mmol / L and 2 hours postprandial blood glucose <8.0mmol / L as the target of treatment, the blood sugar level was measured by the dynamic glucose meter, SDBG, MAGE and the coefficient of variation of fasting blood glucose (CV-FPG) The index. Results The levels of SDBG (1.01 ± 0.32 vs 1.38 ± 0.21), MAGE (2.32 ± 0.97 vs 3.54 ± 1.05) and CV-FPG (9.86 ± 4.45 vs 15.62 ± 5.23) in CSII group were significantly lower than those in MDI group (P <0.05) The number of people with blood glucose was also lower than that of MDI patients, but no statistical significance (P> 0.05). Conclusion More than MD1 is more conducive to the stability of blood glucose.